SCHEMBL31713849

SCHEMBL31713849

C=CC(=O)Nc1ccc(Cl)cc1-c1c(CC)n(CC(=O)Nc2ccc(C(F)(F)F)cc2)c2nc(C3=CCOCC3)nn2c1=O

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ WRN Q14191 1/20 0.52
▸ F11 P03951 2/20 0.34
▸ KRAS P01116 1/20 0.33
▸ EGFR P00533 1/20 0.32
▸ IDO1 P14902 1/20 0.32
▸ TDO2 P48775 1/20 0.32
▸ MEN1 O00255 1/20 0.32
▸ LMNA P02545 1/20 0.32
▸ KMT2A Q03164 1/20 0.32
▸ BTK Q06187 1/20 0.31
▸ TGM2 P21980 1/20 0.31
▸ MAPT P10636 3/20 0.31
▸ TP53 P04637 1/20 0.31
▸ THRB P10828 1/20 0.31
▸ FGFR4 P22455 1/20 0.30
▸ KDM4E B2RXH2 1/20 0.30
▸ POLB P06746 1/20 0.30
▸ L3MBTL1 Q9Y468 1/20 0.30
▸ GPBAR1 Q8TDU6 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31713566 0.96 WRN (0.50) WRNF11KRASEGFRIDO1
SCHEMBL31713802 0.94 WRN (0.51) WRNKRASBTKTGM2MAPT
SCHEMBL31713647 0.92 WRN (0.48) WRNEGFRBTKTGM2MAPT
SCHEMBL31713369 0.92 WRN (0.51) WRNEGFRLMNABTKTGM2
SCHEMBL31713820 0.90 WRN (0.48) WRNEGFRBTKTGM2MAPT
SCHEMBL31713758 0.90 WRN (0.50) WRNEGFRBTKTGM2MAPT
SCHEMBL31713745 0.88 WRN (0.59) WRNEGFRMEN1KMT2ABTK
SCHEMBL31713682 0.88 WRN (0.47) WRNBTKTGM2MAPTKDM4E
SCHEMBL31713805 0.84 WRN (0.51) WRNMAPTTP53KDM4EPOLB
SCHEMBL31713832 0.83 WRN (0.49) WRNLMNAMAPTTP53KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250333419-A1 BICYCLIC COMPOUNDS AS INHIBITORS OF WRN INCYTE CORPORATION (US) 2025-10-30 — — US claimed
US-20250333419-A1 BICYCLIC COMPOUNDS AS INHIBITORS OF WRN INCYTE CORPORATION (US) 2025-10-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250333419-A1 BICYCLIC COMPOUNDS AS INHIBITORS OF WRN WRN, BLM, RECQL WRN 1/4885F11 4266/4885KRAS 793/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback